Product Description
BEBT-758 — SNCA | Parkinson’s Disease: In mice and rats, the siRNA produced robust, sustained SNCA knockdown across multiple brain regions. In NHP (IT 60 mg and 10 mg), CSF a-synuclein decreased by 70% -90% with effects sustained for >30 weeks; preliminary rat tox showed no behavioral, neuroinflammatory, or clinical chemistry liabilities and minimal peripheral exposure. (Sourced from: http://www.bebettermed.com/#pipeline)
Mechanisms of Action: SNCA Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BeBetter Med
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|